<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732563</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000601525</org_study_id>
    <secondary_id>RPCI-I-97306</secondary_id>
    <nct_id>NCT00732563</nct_id>
  </id_info>
  <brief_title>Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Radioguided Detection of Lymph Node Metastasis in Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures using fludeoxyglucose F 18 and a surgical probe may help&#xD;
      find lymph node metastases in patients with early-stage non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 works in detecting&#xD;
      lymph node metastasis in patients with stage I or stage II non-small cell lung cancer that&#xD;
      can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the positive threshold of lymph node radioactivity after fludeoxyglucose F 18,&#xD;
           utilizing the gamma probe, in patients with resectable stage I or II non-small cell lung&#xD;
           cancer.&#xD;
&#xD;
        -  Compare the accuracy of detecting thoracic lymph node metastases using positron emission&#xD;
           tomography-computed tomography (PET-CT) versus the intra-operative hand-held gamma probe&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the ability of the gamma probe to detect lymph node micrometastases, resulting&#xD;
           in upstaging in these patients.&#xD;
&#xD;
        -  Assess the clinical relevance of the gamma probe-detected lymph node metastases by&#xD;
           measuring patient survival, tumor recurrence, impact on patient quality of life, and&#xD;
           cost.&#xD;
&#xD;
      OUTLINE: Patients undergo a positron emission tomography-computed tomography (PET-CT) scan&#xD;
      within 90 days before surgery. Beginning 1-4 hours before surgery on day 1, patients receive&#xD;
      an injection of fludeoxyglucose F 18 (FDG) and a mediastinoscopy is performed. FDG-avid lymph&#xD;
      nodes are obtained and may undergo immunohistochemical analysis or standard analysis.&#xD;
      Patients with mediastinal lymph node micrometastasis do not undergo primary tumor resection.&#xD;
      Patients with ipsilateral mediastinal micrometastases undergo neoadjuvant chemotherapy prior&#xD;
      to surgical resection. Patients with contralateral mediastinal micrometastases undergo&#xD;
      definitive chemoradiotherapy. In the absence of mediastinal lymph node metastases (micro or&#xD;
      macro), complete surgical resection is performed after the mediastinoscopy, including&#xD;
      complete thoracic lymphadenectomy. The tumor and lymph nodes (both from mediastinoscopy and&#xD;
      thoracotomy) undergo radioactivity measurements with the hand-held gamma probe. Fresh tumor&#xD;
      and lymph node samples are stored for future studies.&#xD;
&#xD;
      Patients complete the Short Form 36 Health Survey (SF-36) before surgery and at 1, 3, and 6&#xD;
      months after surgery to assess the potential impact of the gamma probe on patient quality of&#xD;
      life.&#xD;
&#xD;
      After completion of study, patients are followed every 6 months for 2 years, and then&#xD;
      annually for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2008</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate at 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence rate at 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive threshold of lymph node radioactivity</measure>
    <time_frame>within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the accuracy of detecting thoracic lymph node metastases using PET-CT scans versus intra-operative hand-held gamma probe</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability of the gamma probe to detect lymph node micrometastases, resulting in upstaging</measure>
    <time_frame>Within 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Given IV and Orally</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphadenectomy</intervention_name>
    <description>Removal of lymph nodes</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <description>Tumor reduction</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Correlative Study</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Treatment for cancer</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thoracic surgical procedure</intervention_name>
    <description>removal of tissue</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>given IV</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>undergoing radiotherapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of non-small cell lung cancer&#xD;
&#xD;
               -  Stage I-II disease&#xD;
&#xD;
               -  Resectable disease&#xD;
&#xD;
          -  Planning to undergo surgical resection&#xD;
&#xD;
          -  No tumors that are not fludeoxyglucose F 18 (FDG)-avid on PET scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No previous allergic reaction to fludeoxyglucose F 18&#xD;
&#xD;
          -  No contraindication to a pulmonary lobectomy and lymphadenectomy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chukwumere E. Nwogu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 9, 2008</study_first_submitted>
  <study_first_submitted_qc>August 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

